{
  "docId": "019de070-c9e1-7644-aac7-afa340d8795d",
  "docSlug": "fc9db8b68eed863ebdeb09cbc0c7e18a",
  "documentTitle": "AstraZeneca | Investor Day Presentation Deck | 86 slides",
  "authorId": "astrazeneca",
  "authorName": "AstraZeneca",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2021-03-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 18,
  "pageCount": 86,
  "prevPage": 17,
  "nextPage": 19,
  "slideType": "key_messages",
  "function": "summarize",
  "density": "overcrowded",
  "nDataPoints": 10,
  "notes": "The slide uses a three-column layout to present project metrics, chemical safety improvements, and biological efficacy results.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de070-c9e1-7644-aac7-afa340d8795d/18",
  "deckHref": "/decks/019de070-c9e1-7644-aac7-afa340d8795d",
  "deckJsonHref": "/decks/019de070-c9e1-7644-aac7-afa340d8795d.json",
  "deckAnchorHref": "/decks/019de070-c9e1-7644-aac7-afa340d8795d#slide-18",
  "components": [
    {
      "bbox": {
        "h": 0.4,
        "w": 0.25,
        "x": 0.68,
        "y": 0.35
      },
      "kind": "chart",
      "text": "In vivo activity of PROTACS for a cardiovascular target",
      "attrs": null,
      "subkind": "dot",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "532d11ce-0cbc-49e0-9602-4e8cc9b19ab2",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.25,
        "x": 0.05,
        "y": 0.6
      },
      "kind": "metric",
      "text": "Five E3 ligases enabled for project application",
      "attrs": null,
      "subkind": "big-number",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "074b1c45-788b-48a6-aa86-6731018051e7",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.25,
        "x": 0.05,
        "y": 0.75
      },
      "kind": "metric",
      "text": "Three Projects in lead optimisation",
      "attrs": null,
      "subkind": "big-number",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3d5f2fde-17b5-46b2-a0c6-a6d32682b62c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.2,
        "x": 0.05,
        "y": 0.3
      },
      "kind": "metric",
      "text": "16 PROTAC projects",
      "attrs": null,
      "subkind": "big-number",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "826544d0-72a5-4f48-a03d-19f628df5e4f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.25,
        "x": 0.05,
        "y": 0.45
      },
      "kind": "metric",
      "text": "Five Projects with in vivo efficacy",
      "attrs": null,
      "subkind": "big-number",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "92dea842-76ed-4d9c-b5b4-5b8802054883",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.3,
        "x": 0.03,
        "y": 0.9
      },
      "kind": "source-note",
      "text": "Source: Pike et al. Drug Discov. Today (2020); Edmondson et al. BioOrg. Med. Chem. Lett. (2019).",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "bcf2d5ba-530b-484f-abc3-23aa04fd5009",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.2,
        "w": 0.3,
        "x": 0.35,
        "y": 0.65
      },
      "kind": "table",
      "text": "Potency 260 nM vs 161 nM; Stability <30 min vs >200 h; Racemisation Yes vs No; Teratogenic Yes vs No",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "265cfd1b-56d5-49d2-ae95-75007ae7e8f1",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.8,
        "x": 0.03,
        "y": 0.03
      },
      "kind": "title",
      "text": "Novel PROTAC chemistry advances project portfolio",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0a5bedf4-4197-40d6-8351-f1a5b6f7d541",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Table data",
      "slug": "table-data",
      "agent": null,
      "layer": "slide",
      "matchId": "3a27ef82-6312-4bea-9cf3-ebb6745c90f9",
      "evidence": "table/data: Potency 260 nM vs 161 nM; Stability <30 min vs >200 h; Racemisation Yes vs No; Teratogenic Yes vs No",
      "confidence": 0.9
    }
  ],
  "frameworks": [],
  "arcBeats": [],
  "loops": [
    {
      "to": 22,
      "from": 16,
      "name": "Hypothesis Test",
      "slug": "42-hypothesis-test",
      "bestFor": "Strategy validation, due diligence, research presentations",
      "matchId": "5626f9b9-0f70-4f98-b854-9c52634de590",
      "evidence": "Slides 16-22 outline the company's use of AI in drug discovery",
      "position": 1,
      "objective": "Present AstraZeneca's approach to identifying new targets through AI-enabled big data",
      "structure": "The Hypothesis -> Test 1 (Supports/Refutes) -> Test 2 (Supports/Refutes) -> Conclusion (Validated/Pivoted)",
      "confidence": 0.7,
      "description": "State a hypothesis upfront, then systematically prove or disprove it with evidence"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}